Dr Reddy's launches Fulvestrant injection in US

Our Bureau Hyderabad | Updated on September 07, 2020

Dr Reddy’s is working to commercialise this lice management product through partners

Dr. Reddy’s Laboratories Ltd has launched Fulvestrant Injection per single-dose syringe, a therapeutic equivalent generic version of Faslodex (fulvestrant) Injection approved by the U.S. Food and Drug Administration (USFDA).

The Faslodex brand and generic market had U.S. sales of approximately $407 million for the most recent twelve months ending in June 2020 according to IQVIA Health

Dr. Reddy’s Fulvestrant Injection per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes. Faslodex is a trademark of the AstraZeneca group of companies.

Published on September 07, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like